

In the Claims

Please cancel Claims 27, 34, 35, and 38 without prejudice or disclaimer.

Please replace claims 1, 28-33, 36, 37 and 39-41, with the following:

D2  
1. A method for treating an acute or chronic inflammatory disease which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein and at least one COX2 inhibitor, wherein said TNF binding protein and COX2 inhibitor are administered separately or in combination and wherein the administration of the TNF binding protein is prior, concurrent, or post-administration of the COX2 inhibitor.

28. The method of treatment according to claim 1, wherein the COX2 inhibitor is celecoxib.

29. The method of treatment according to claim 1, wherein the acute or chronic inflammatory disease is a TNF-mediated disease.

D3  
30. The method of treatment according to claim 1, wherein said TNF binding protein comprises a sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.

31. The method of treatment according to claim 1, wherein said TNF binding protein comprises a sequence which is at least about 90% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.

32. The method of treatment according to claim 1, wherein said TNF binding protein comprises a sequence which is at least about 95% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.

33. The method of treatment according to claim 1, wherein said TNF binding protein comprises a sequence which is at least about 99% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.

36. The method of treatment according to claim 1, wherein said TNF binding protein is non-glycosylated.

D4 37. The method of treatment according to claim 1, wherein said TNF binding protein is glycosylated.

39. The method of treatment according to claim 1, wherein said TNF binding protein is produced by recombinant DNA methods.

D5 40. The method of treatment according to claim 1, wherein said inflammatory disease is an inflammatory disease of a joint.

41. The method of treatment according to claim 1, wherein said inflammatory disease is rheumatoid arthritis.